Skip to content
Review Open access

Nanomedicine beyond carriers — devices, cells & living therapeutics

Sep 2026 · Biomedical microdevices · Vol 28 · 0 citations · 323 references
Medicine

TL;DR

This perspective summarizes the current landscape of biomedical nanotechnologies and outlines how their continued evolution positions nanomedicine as an enabling science driving the next generation of therapeutics.

Abstract

Nanomedicine has progressed far beyond its early role as an experimental drug-carrier toolbox and today stands as a clinically validated enabling technology. Liposomal formulations and albumin-bound nanoparticles have transformed cancer therapy, while lipid nanoparticle (LNP) platforms accelerated the rapid development and global deployment of SARS-CoV-2 mRNA vaccines—demonstrating how nanoscale engineering can reshape therapeutic response, manufacturing speed, and public health impact. With these successes as foundation, the field is rapidly expanding into more sophisticated delivery systems including cell-hitchhiking nanoparticles, biomimetic multivalent vaccines, implantable immunotherapy depots, high-loading polymeric micelles, organ-targeted gene and RNA carriers, and bio-hybrid extracellular vesicle and mitochondrial therapies. These platforms aim not only to transport drugs, but to modulate immunity, direct regeneration, and enable precision intervention at the cellular and molecular scale. This perspective summarizes the current landscape of biomedical nanotechnologies and outlines how their continued evolution positions nanomedicine as an enabling science driving the next generation of therapeutics.

Read PDF

Similar papers

#gene editing Review Open access Aug 2026

Nanomaterial-based drug delivery systems: From intelligent delivery to clinical translation and precision nanomedicine.

A structured translational roadmap is proposed that prioritizes biologically predictive design, fit-for-purpose safety assessment, scalable good manufacturing practice production, early regulatory alignment, and clinically meaningful benefit over unnecessary structural complexity.

Yi Li, Rui Luo, Yuxuan Li et al. · 1 citation
Open access Sep 2026

Innovative nanomedicine strategies for precision-controlled targeted drug delivery: recent preclinical progress

Current preclinical evidence supports nanomedicine as a central pillar of precision drug delivery, with future progress expected to focus on adaptive, multifunctional, and patient-specific platforms that align with the principles of personalized medicine.

Ashna Sureshkumar, P. Balu · 0 citations
Review Open access Sep 2026

Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches

This review examines the main classes of nanoplatforms currently explored for cancer therapy, including inorganic, polymeric, lipid-based, and hybrid organic–inorganic systems, and considers emerging directions in AI-guided nanoparticle engineerization design and natural-compound-based nanomedicines, both of which are...

C. Boncristiani, F. Baldassarre, Khadija Eddahaoui et al. · 0 citations
Sep 2026

Exosome-Based Drug Delivery: Prospects in Regenerative Medicine and Cancer.

Exosomes have the potential to become next-generation delivery systems that revolutionize cancer therapy and regenerative medicine treatment approaches with further development.

Pratik Rajale, N. Meshram, Shreya Kalbandhe et al. · 0 citations
Review Open access Sep 2026

Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives

This review paper provides an integrated and critical perspective on next-generation nanomedicine by connecting nanocarrier design with tumor-specific accumulation, intracellular trafficking, stimuli-responsive drug release, combination therapy and clinical translation.

Biswajit Mohanty, P. Saikia, Piyush Pandey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.